Literature DB >> 33190035

Dithiolation indolizine exerts viability suppression effects on A549 cells via triggering intrinsic apoptotic pathways and inducing G2/M phase arrest.

Guanting Li1, Xianwei Wu1, Peng Sun2, Zhiyang Zhang1, Enxian Shao1, Jianping Mao3, Hua Cao4, Hongliang Huang5.   

Abstract

Indolizine derivatives have been reported for the treatment of numerous diseases. However, few studies were carried out for non-small cell lung cancer (NSCLC). We synthesized series of indolizine compounds. The results of MTT assay showed compound 8 (C8) markedly inhibited the proliferation of A549 cells, however, C8 (15, 30 μg/mL) had little cytotoxicity in other cell lines (SH-SY5Y, HepG2, and BEAS-2B cells), Hoechst staining and JC-1 staining showed that C8 induced changes in the nucleus morphology, increased the loss in mitochondrial membrane potential in A549 cells. The results of flow cytometry manifested that cell cycle of the cells was arrested in the G2 / M phase by C8, ROS levels and the proportion of apoptosis of cells increased. We performed western blotting analysis to detect the expression levels of apoptosis and cycle-related proteins. These results validated that the apoptosis of cells was triggered by endoplasmic reticulum stress (ERS) and the PI3K/Akt-mediated mitochondrial pathway collaboratively. Besides, the utilization of PI3K/Akt inhibitors and p53 inhibitors further proves the above argument and C8-induced cycle arrest of A549 cells is majorly regulated by p53. C8 induced the accumulation of ROS contents involved in mitochondrial damage. The proliferation of A549 cells was inhibited after treatment with the compound, which induced apoptosis and cycle arrest of cells. It is suggested that C8(dithiolation indolizine) is a potential candidate compound against non-small cell lung cancer.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  A549 cells; Apoptosis; Endoplasmic reticulum stress (ERS); G2/M arrest; Mitochondrial pathway

Year:  2020        PMID: 33190035     DOI: 10.1016/j.biopha.2020.110961

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Long noncoding RNA BACE1-antisense transcript plays a critical role in Parkinson's disease via microRNA-214-3p/Cell death-inducing p53-target protein 1 axis.

Authors:  Lina Li; Hongjuan Wang; Huicang Li; Xin Lu; Yanxiang Gao; Xiaofeng Guo
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Long non-coding RNA DHRS4 antisense RNA 1 inhibits ectopic endometrial cell proliferation, migration, and invasion in endometriosis by regulating microRNA-139-5p expression.

Authors:  Xuan Cui; Shisan Zhou; Yongtao Lin
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Anticancer Action of Xiaoxianxiong Tang in Non-Small Cell Lung Cancer by Pharmacological Analysis and Experimental Validation.

Authors:  Rongzhen Ding; Lijing Jiao; Shuliu Sang; Yinan Yin; Yichao Wang; Yabin Gong; Ling Xu; Ling Bi
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-13       Impact factor: 2.629

4.  FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway.

Authors:  Shike Yan; Bing Zhang; Jingwen Feng; Haigang Wu; Namin Duan; Yamin Zhu; Yueliang Zhao; Shuang Shen; Kai Zhang; Wenhui Wu; Ning Liu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

Review 5.  Mammalian AKT, the Emerging Roles on Mitochondrial Function in Diseases.

Authors:  Xiaoxian Xie; Ruonan Shu; Chunan Yu; Zhengwei Fu; Zezhi Li
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

6.  MicroRNA-30a contributes to pre-eclampsia through regulating the proliferation, apoptosis, and angiogenesis modulation potential of mesenchymal stem cells by targeting AVEN.

Authors:  Fangle Gu; Dan Lu; Liying Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.